A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma

Trial Profile

A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Carotuximab (Primary) ; Pazopanib
  • Indications Haemangiosarcoma; Sarcoma; Soft tissue sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors TRACON Pharmaceuticals
  • Most Recent Events

    • 05 Jun 2017 Results of presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, according to a TRACON Pharmaceuticals media release.
    • 28 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 28 Nov 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top